Cargando…

An Exceptionally Favorable Response to Etoposide and Cisplatin

A 66-year-old female with multiple medical co-morbidities was diagnosed with limited-stage small cell lung carcinoma (SCLC) about 11 years ago, back in 2004. The patient was treated with concomitant chemotherapy and radiotherapy, along with prophylactic whole brain radiation. She received a total of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valecha, Gautam, Vennepureddy, Adarsh, Ibrahim, Uroosa, Odaimi, Marcel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725742/ https://www.ncbi.nlm.nih.gov/pubmed/26848411 http://dx.doi.org/10.7759/cureus.418

Ejemplares similares

Correlation of Antiglobulin Reactivity and Severity of Pancytopenia in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature
por: Thumallapally, Nishitha, et al.
Publicado: (2018)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Synchronous Pulmonary Neoplasms: A Chance Occurrence or is There More Than Meets the Eye?
por: Ibrahim, Uroosa, et al.
Publicado: (2018)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
por: Gong, Baocheng, et al.
Publicado: (2021)

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
por: Gong, Baocheng, et al.
Publicado: (2022)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
por: Panomuppakarn, Nathamon, et al.
Publicado: (2017)

An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
por: Bilinski, Pretoria, et al.
Publicado: (2020)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

Leiomyosarcoma of the Penis, an Exceptional Entity
por: Romero Gonzalez, Edwin Javier, et al.
Publicado: (2015)

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

A Case of an Enigmatic Pulmonary Infiltrate
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia
por: Parylo, Sara, et al.
Publicado: (2017)

A Rare Case of Aggressive Systemic Mastocytosis With Skeletal Osteosclerotic Lesions on Presentation: A Diagnostic Conundrum
por: Ghorpade, Rina, et al.
Publicado: (2022)

Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report
por: Colton, Bradley, et al.
Publicado: (2016)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Exceptional Location of a Papillary Carcinoma of the Thyroid
por: Thouil, Afaf, et al.
Publicado: (2023)

Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide
por: Biasoli, D, et al.
Publicado: (2013)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
por: Watanabe, R, et al.
Publicado: (2003)

Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer
por: Nieder, Carsten, et al.
Publicado: (2017)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
por: Isaka, Yuri, et al.
Publicado: (2023)

Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature
por: Vennepureddy, Adarsh, et al.
Publicado: (2015)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
por: Sternberg, Cora N., et al.
Publicado: (2022)

High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022)

Facial Paralysis and Hearing Loss: A Rare Manifestation of Prostate Cancer Metastases
por: Ibrahim, Uroosa, et al.
Publicado: (2017)

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.
por: Bonacci, R., et al.
Publicado: (1998)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
por: Bonfante, Giulia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pjbqfbe692prngmhcvukd07c47